Deuterium Metabolic Imaging to measure hepatic fructose metabolism


Published June 30, 2025

Chronic intake of high amounts of fructose has been linked to the development of metabolic disorders caused by the almost complete clearance of fructose by the liver. However, direct measurement of hepatic fructose uptake is complicated by the fact that the portal vein is difficult to access. 

Dr. Arjan Hendriks, from the University Medical Center Utrecht, applied for access at the PRIME Node to explore the opportunities and potential effectiveness of different deuterated compounds to map body metabolism with deuterium metabolic imaging (DMI), and thanks to the data obtained during this access he developed a new, non-invasive method to measure hepatic fructose uptake and metabolism, based on administration of [6,6’-2H2]fructose followed by DMI. 

issue concentration of deuterated glucose and/or fructose
Tissue concentration of deuterated glucose and/or fructose, and of deuterated water as a function of time during and after a bolus injection versus a slow IV infusion of [6,6’-2H2]glucose and [6,6’-2H2]fructose. Figures have been adapted from: https://doi.org/10.3389/fphys.2023.1198578 Used under a Creative Commons CC-BY 4.0 license.

The application of this method in mice showed a higher extraction and faster turnover of fructose in the liver, as compared with glucose. Furthermore, comparing high concentration bolus injections with a slow low concentration infusion gave more insight into the fructose build up in the liver as compared to glucose. DMI with [6,6’-2H2]glucose and [6,6’-2H2]fructose could potentially contribute to a better understanding of healthy human liver metabolism and aberrations in metabolic diseases.

In vivo anatomical 3D MR images
In vivo anatomical 3D MR images were acquired as a guide to perform B0 shimming on a voxel (orange) and to position the DMI grid (green). Figures have been adapted from: https://doi.org/10.3389/fphys.2023.1198578. Used under a Creative Commons CC-BY 4.0 license.

This is an example of research that can be supported by the Euro-BioImaging’s PRIME Node.

About Euro-BioImaging’s PRIME Node

The Dutch Preclinical Imaging Center PRIME – Molecular Imaging Node is a dual-sited Node that consists of the Preclinical Imaging Centre (PRIME), Radboud University Nijmegen, and the Intravital Microscopy Facility (IMF), Hubrecht Institute, Utrecht. This Node is a centralized facility for multimodality imaging of small animals, such as mice and rats. PRIME is the only centre in the Netherlands where more than four imaging modalities for small animal imaging are housed under one roof in one facility. The intravital microscopy laboratory offers advanced genetic mouse models and has heavily invested in state-of-the-art imaging of small animals using multiphoton microscopy. PRIME functions as single-site facility for small animal imaging with state-of-the-art equipment and expertise for magnetic resonance imaging (MRI), positron emission tomography (PET/CT), single photon emission computed tomography (SPECT/CT), intravital multi-photon fluorescence imaging (MPFI) and high frequency ultrasound imaging (HFUS).


More news from Euro-BioImaging

Portuguese BIN Node staff with Ale and Erika

July 18, 2025

Visiting the Portuguese Brain Imaging Network (BIN) Node

In June 2025, some of the Euro-BioImaging Hub staff attended the Annual congress of the European Association for Cancer Research (EACR) in Lisbon,…

Four Shades of Pollen Allergy, by Tomáš Figura, Faculty of Science, Charles University, Prague, Czechia

July 17, 2025

Congratulations to the winners of the “Spring” imaging contest

We are delighted to announce the winners of the “Spring” round of our Four Seasons of the Invisible Imaging Contest. Launched in March 2025,…

Sylvia Le Devedec Mentoring masterclass EVOLVE

July 15, 2025

EVOLVE Mentoring Masterclass: A FAIR vision on imaging core facilities from Sylvia E. Le Dévédec

As part of the EVOLVE Mentoring Masterclass series, Euro-BioImaging was proud to host Dr. Sylvia E. Le Dévédec on June 23, 2025, to share…